Email updates

Keep up to date with the latest news and content from International Journal of Pediatric Endocrinology and BioMed Central.

Open Access Open Badges Case report

A novel CaSR mutation presenting as a severe case of neonatal familial hypocalciuric hypercalcemia

Ksenia N Tonyushkina1*, Stephen O’Connor2 and Nancy S Dunbar1

Author Affiliations

1 Baystate Children’s Hospital, Tufts University School of Medicine, 759 Chestnut St. Dept of Pediatrics, Springfield, MA 01199, USA

2 Baystate Medical Center, Tufts University School of Medicine, 759 Chestnut St. Dept of Radiology, Springfield, MA 01199, USA

For all author emails, please log on.

International Journal of Pediatric Endocrinology 2012, 2012:13  doi:10.1186/1687-9856-2012-13

Published: 23 May 2012



Familial Hypocalciuric Hypercalcemia (FHH) is a generally benign disorder caused by heterozygous inactivating mutations in the Calcium-Sensing Receptor (CaSR) gene resulting in altered calcium metabolism.


We report a case of unusually severe neonatal FHH due to a novel CaSR gene mutation that presented with perinatal fractures and moderate hypercalcemia.

Case overview

A female infant was admitted at 2 weeks of age for suspected non-accidental trauma (NAT). Laboratory testing revealed hypercalcemia (3.08 mmol/L), elevated iPTH (20.4 pmol/L) and low urinary calcium clearance (0.0004). Radiographs demonstrated multiple healing metaphyseal and rib fractures and bilateral femoral bowing. The femoral deformity and stage of healing were consistent with prenatal injuries rather than non-accidental trauma (NAT). Treatment was initiated with cholecalciferol, 400 IU/day, and by 6 weeks of age, iPTH levels had decreased into the high-normal range. Follow up radiographs demonstrated marked improvement of bone lesions by 3 months. A CaSR gene mutation study showed heterozygosity for a T>C nucleotide substitution at c.1664 in exon 6, resulting in amino acid change I555T in the extracellular domain consistent with a missense mutation. Her mother does not carry the mutation and the father is unknown. At 18 months of age, the child continues to have relative hyperparathyroidism and moderate hypercalcemia but is otherwise normal.


This neonate with intrauterine fractures and demineralization, moderate hypercalcemia and hyperparathyroidism was found to have a novel inactivating missense mutation of the CaSR not detected in her mother. Resolution of bone lesions and reduction of hyperparathyroidism was likely attributable to the natural evolution of the disorder in infancy as well as the mitigating effect of cholecalciferol treatment.

FHH; Neonatal hyperparathyroidism; Hypercalcemia; NHPT; CaSR; Vit D